Samuel SK Lam

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Manipulation of immune system toward the rejection of established cancers has become the standard of care in some patients. Here we propose the development of an in situ autologous cancer vaccine, inCVAX, for the treatment of hepatocellular cancer (HCC). inCVAX is based on the induction of local immunogenic cancer cell death combined with local dendritic(More)
  • 1